GCFC2

Across TCGA pan-cancer cohorts, GCFC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GCFC2 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GCFC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GCFC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where GCFC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.951	0.381	.006	16	view →
LUAD	DFS	Tertile	All	0.722	0.348	.003	14	view →
LSCC	DFS	Quartile	All	1.000	0.909	.010	5	view →
UCEC	DFS	Quartile	All	1.000	0.902	.040	4	view →
HNSC	DFS	Quartile	III,IV	0.333	0.855	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GCFC2–PDAC (OS)

Open the PDAC breakdown →